Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.

In addition, two trials examined the use of adjuvant TT for patients with BRAF -mutant resected melanoma: The BRIM-8 trial investigated the efficacy of adjuvant single-agent vemurafenib compared with placebo but did not reach statistical significance with regard to the prespecified endpoint of disease-free survival and thus single-agent vemurafenib is not recommended for adjuvant melanoma therapy. 11 By contrast, the COMBI-AD trial, which tested adjuvant dabrafenib+trametinib (DT) for resected, BRAF -mutant stage III melanoma met its primary en

also in 111,027 other papers